Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index

布洛芬 骨关节炎 医学 沃马克 药理学 不利影响 麻醉 病理 替代医学
作者
Franz Singer,Franz Mayrhofer,G Klein,Reinhold Hawel,ChJ. Kollenz
出处
期刊:International Journal of Clinical Pharmacology and Therapeutics [Dustri-Verlag]
卷期号:38 (01): 15-24 被引量:29
标识
DOI:10.5414/cpp38015
摘要

OBJECTIVE: Treatment with non-steroidal anti-inflammatory drugs is the most common pharmacological therapy of rheumatic diseases. For the symptomatic treatment of painful disorders a dose-response relationship of the NSAID should be a basic requirement, which is difficult to be proven in studies because rheumatic diseases are heterogenous in terms of clinical involvement. The aim of this double-blind randomized trial was to compare the isolated active enantiomer dexibuprofen (S(+)-ibuprofen) with the double dose of racemic ibuprofen and to show a dose-response relationship of dexibuprofen in painful osteoarthritis of the hip. METHODS: 178 patients were randomly assigned to dexibuprofen 600/1,200 mg or racemic ibuprofen 2,400 mg daily. The primary endpoint was the improvement of the WOMAC osteoarthritis index after 15 days of therapy. The analysis was by intention to treat. RESULTS: The evaluation of the WOMAC OA index showed statistically significant equivalence of dexibuprofen 400 mg t.i.d. compared with racemic ibuprofen 800 mg t.i.d. by a Mann-Whitney statistic of 0.578 and the corresponding lower bound of the 95% confidence interval of 0.498. The test for superiority of dexibuprofen was borderline significant with p = 0.055. Dexibuprofen 400 mg t.i.d. and dexibuprofen 200 mg t.i.d. showed a statistically significant dose-response relationship in improving the WOMAC OA index (p = 0.023). Patients suffered from adverse drug reactions, mainly gastrointestinal disorders, 13.34% on dexibuprofen 200 mg, 15.25% on dexibuprofen 400 mg and 16.94% on racemic ibuprofen 800 mg. CONCLUSIONS: The active enantiomer dexibuprofen (S(+)-ibuprofen) proved to be an effective non-steroidal anti-inflammatory drug with a significant dose-response relationship in patients with painful osteoarthritis of the hip. Compared with racemic ibuprofen half of the daily dose of dexibuprofen shows at least equivalent efficacy. In contrast to pharmacokinetic data, the additional administration of R(-)-ibuprofen in form of racemate does not contribute to the clinical efficacy of racemic ibuprofen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
默蓝完成签到 ,获得积分10
刚刚
巴拉巴拉完成签到,获得积分10
刚刚
沐风完成签到 ,获得积分10
刚刚
cz完成签到,获得积分10
刚刚
要减肥完成签到,获得积分10
1秒前
Jonathan完成签到,获得积分10
1秒前
孤独芷烟发布了新的文献求助10
1秒前
大白完成签到,获得积分10
2秒前
2秒前
一辉完成签到,获得积分10
2秒前
2秒前
12完成签到,获得积分10
3秒前
浮生若梦完成签到,获得积分10
3秒前
科研通AI65的应助被369ninja采纳,获得200
3秒前
jazz完成签到,获得积分10
3秒前
勤恳丹妗完成签到,获得积分10
3秒前
灞波儿奔的应助被灶鲜森采纳,获得10
3秒前
黄小小发布了新的文献求助10
3秒前
Puffkten完成签到 ,获得积分10
4秒前
阔达尔冬完成签到,获得积分10
4秒前
噢噢完成签到,获得积分10
4秒前
4秒前
有缘不必求份完成签到,获得积分10
5秒前
nuantong1shy完成签到,获得积分10
5秒前
林川完成签到,获得积分10
5秒前
MZP完成签到,获得积分10
6秒前
TaoJ发布了新的文献求助10
6秒前
7秒前
张津浩完成签到,获得积分10
7秒前
Austin111327发布了新的文献求助10
8秒前
孙士淼完成签到 ,获得积分10
8秒前
8秒前
妮妮完成签到 ,获得积分10
9秒前
车剑锋完成签到,获得积分0
9秒前
10秒前
加油吧少年完成签到,获得积分10
10秒前
bluehand完成签到,获得积分0
11秒前
强砸完成签到,获得积分10
11秒前
ReynaLi完成签到 ,获得积分10
12秒前
渔婆完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039